Most Recent
Pharmaceutical companies Sanofi and Bristol-Myers Squibb are liable for losses to the federal government for excess subsidies it allegedly paid for the blood-thinner Plavix after an unjustified court injunction prevented the release of a generic version of the top-selling drug, an appeals court has heard.
A French geographical indication body has triumphed in its opposition to a bid to trade mark the name 'Chateau Roquehort' for dairy products, with a delegate finding that Australians would wrongly associate the name with blue cheeses from France.
The High Court will decide whether the Full Court was wrong to overturn a $26.3 million judgment for Danish drug maker H Lundbeck in its long-running patent battle with generic drug maker Sandoz over the patent for blockbuster antidepressant Lexapro.
Nine-owned Fairfax will have to pay out over $2 million in legal fees after being hit with indemnity costs on top of a $280,000 judgment in its defamation spat with venture capitalist Dr Elaine Stead for its "Micawber-like" approach to the case.
Facebook and its subsidiary Instagram are pushing for a competition dispute brought by an Australian social media startup to be heard on their home turf in the state of California.
Venture capitalist Dr Elaine Stead is seeking indemnity costs after being awarded $280,000 in her defamation case against Nine-owned Fairfax, which she accuses of rejecting several settlement offers with "bugger off letters" and engaging in a "petulant campaign" of media coverage post-judgment.
The Federal Court has delayed a 15-day hearing in a pneumococcal vaccine patent dispute between Merck Sharp & Dohme and Pfizer after the sudden death of a family member of one of Pfizer's expert witnesses.
Concerns behind criticism that courts aren't equipped to assess a class action funder's commission are exaggerated, and the fixing by judges of reasonable remuneration, at least in other cases, is nothing new, a Federal Court judge has said.
While a Federal Court judge recently promised to advance a long-running criminal cartel case against several investment banks and individuals over a $2.5 billion ANZ share placement, a separate judge will soon hear a privilege dispute over documents from whistleblower JPMorgan that promises to further delay the case.
Venture capitalist Dr Elaine Stead has been awarded $280,000 in her defamation case against the Nine-owned Australian Financial Review after the Federal Court found she suffered hurt and damage to her reputation through a "targeted campaign of offensive mockery" about her role in collapsed investment firm Blue Sky Alternative Investments.